Abstract:
The present invention discloses a capsule endoscope and a method to prevent the capsule from being covered by a residue or mucous in a patient's digestive tract. The capsule endoscope comprises an improved surface, preventing a residue or mucous to adhere onto the surface of the capsule, and in the unlikely event that a residue or a mucous is collected by the capsule the improved surface can allow an easy and successful clean before an image is taken.
Abstract:
The present invention discloses a capsule endoscope and a method to prevent the capsule from being covered by a residue or mucous in a patient's digestive tract. The capsule endoscope comprises an improved surface, preventing a residue or mucous to adhere onto the surface of the capsule, and in the unlikely event that a residue or a mucous is collected by the capsule the improved surface can allow an easy and successful clean before an image is taken.
Abstract:
FIG. 1 is a top perspective view of a bubble machine showing my new design; FIG. 2 is a bottom perspective view thereof; FIG. 3 is a right perspective view thereof; FIG. 4 is a front elevation view thereof; FIG. 5 is a left side elevation view thereof; FIG. 6 is a right side elevation view thereof; FIG. 7 is a top plan view thereof; FIG. 8 is a bottom plan view thereof; FIG. 9 is a partial enlarged view of FIG. 4; and, FIG. 10 is a partial enlarged view of FIG. 8. Broken lines in the drawings depict portions of the bubble machine that form no part of the claimed design. The additional broken lines surrounding the detail views are for annotative purposes only and form no part thereof.
Abstract:
The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.
Abstract:
The invention relates to polymers useful in optoelectronic devices and comprising structural unit of formula I: wherein R1 and R2 are independently at each occurrence, hydrogen, a C1-C20 aliphatic radical, a C3-C20 aromatic radical, or a C3-C20 cycloaliphatic radical; R3 is H or alkyl; a and b are, independently at each occurrence 0, or an integer ranging from 1 to 3; and Ar is a direct bond or aryl.
Abstract:
Organic compounds of formula I may be used in optoelectronic devices wherein R1 is, independently at each occurrence, a C1-C20 aliphatic radical, a C3-C20 aromatic radical, or a C3-C20 cycloaliphatic radical; R2 is, independently at each occurrence, a C1-C20 aliphatic radical, a C3-C20 aromatic radical, or a C3-C20 cycloaliphatic radical; a is, independently at each occurrence, an integer ranging from 0-4; b is, independently at each occurrence, an integer ranging from 0-3; Ar1 is a direct bond or heteroaryl, aryl, or alkyl or cycloalkyl; Ar2 is heteroaryl, aryl, or alkyl or cycloalkyl; c is 0, 1 or 2; and n is an integer ranging from 2-4.
Abstract:
The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof which possess CSF-IR kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
Abstract:
Compound of formula C is made by reacting a compound of formula A with an pyridyl boronic acid or pyridyl borate ester to form a compound of formula B; and combining the compound of formula B with a pyridyl dihalide to form the compound of C; wherein R3, R4, R5, R6 and R7 are, independently at each occurrence, a C1-C20 aliphatic radical, a C3-C20 aromatic radical, or a C3-C20 cycloaliphatic radical; X is, independently at each occurrence, CH or N; Y is chloro or bromo; Z is bromo or iodo; and when Y is bromo, Z is iodo; d, e, and g are, independently at each occurrence, an integer ranging from 0-4; f is an integer ranging from 0-2; and h is an integer ranging from 0-3.
Abstract:
The invention relates to a polymer comprising structural unit of formula II: wherein R1, R2, R3, R4, R5, R6 and R7 are independently at each occurrence a C1-C20 aliphatic radical, a C3-C20 aromatic radical, or a C3-C20 cycloaliphatic radical; a, b, d, e and f are independently at each occurrence 0, or an integer ranging from 1 to 4; c and g are independently at each occurrence 0, or an integer ranging from 1 to 3. In another aspect, the invention relates to monomers for preparing the polymers. In yet another aspect, the invention relates to an optical electronic device comprising a polymer comprising structural unit of formula II.
Abstract:
Compounds of formula I may be used in optoelectronic devices wherein R1 is, independently at each occurrence, a C1-C20 aliphatic radical, a C3-C20 aromatic radical, or a C3-C20 cycloaliphatic radical; a is, independently at each occurrence, an integer ranging from 0-4; b is 0, 1 or 2; Ar1 is a direct bond or heteroaryl, aryl, or alkyl or cycloalkyl; Ar2 is heteroaryl, aryl, or alkyl or cycloalkyl; c is an integer ranging from 1-7; and n is an integer ranging from 2-4.